The risk of long COVID was two to three times higher after the initial infection (14.8%) than after first (5.8%) or second (5.3%) reinfections.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
The group agreed on a goal of vaccinating at least 70% of the world's population by the middle of next year.
A third Pfizer COVID-19 vaccine dose is 92% more effective in reducing severe COVID-related outcomes than two doses of the same vaccine received at least 5 months previously, according to a large real-world study late last week in The Lancet.
The acting FDA chief says the move will bring us closer to a sense of normalcy.
The secondary attack rate was 25% in fully vaccinated people and 38% in the unvaccinated.
The authors say all eligible people should get the vaccine ASAP, including those previously infected.
Cancer patients who received systemic treatment like chemotherapy or radiation in the 3 months before testing positive for COVID-19 were at increased risk of death, admission to an intensive care unit (ICU), and hospitalization, according to a study yesterday in JAMA Oncology.
The cheap drug fluvoxamine reduced the need for a long emergency department visit or a hospital stay.
Of parents polled, 30% will definitely not get their child vaccinated, and 33% will wait and see.
Also, a syringe shortage looms, and African nations lag woefully in COVID-19 vaccine uptake.
The monoclonal antibody sotrovimab reduced the risk of hospitalization or death from COVID-19 by 85% compared with placebo, according to an interim analysis of a phase 3 clinical trial published yesterday in the New England Journal of Medicine.
